Quinolones for treatment of human brucellosis: Critical review of the evidence from microbiological and clinical studies

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 22-33

  Falagas, Matthew E ^a,b,c   Bliziotis, Ioannis A ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 4 OXO 1,8 NAPHTHYRIDINE 3 CARBOXYLIC ACID; AMIKACIN; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; CLINAFLOXACIN; COTRIMOXAZOLE; DIFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; GATIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; NALIDIXIC ACID; NETILMICIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PIPEMIDIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TETRACYCLINE; UNINDEXED DRUG;

BONE INFECTION; BRUCELLA MELITENSIS; BRUCELLOSIS; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER DYSFUNCTION; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SPONDYLITIS;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; BRUCELLOSIS; HUMANS;

EID: 29944436842     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.22-33.2006     Document Type: Short Survey

References (66)

1. Agalar, C., S. Usubutun, and R. Turkyilmaz. 1999. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur. J. Clin. Microbiol. Infect. Dis. 18:535-538.
2. Akdeniz, H., H. Irmak, O. Anlar, and A, P. Demiroz. 1998. Central nervous system brucellosis: presentation, diagnosis and treatment. J. Infect. 36:297-301.
3. Akova, M., D. Gur, D. M. Livermore, T. Kocagoz, and H. E. Akalin. 1999. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob. Agents Chemother. 43:1298-1300.
4. Akova, M., O. Uzun, H. E. Akalin, M. Hayran, S. Unal, and D. Gur. 1993. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob. Agents Chemother. 37:1831-1834.
5. al Eissa, Y. A., A. M. Kambal, M. N. al Nasser, S. A. al Habib, I. M. al Fawaz, and F. A. al Zamil. 1990. Childhood brucellosis: a study of 102 cases. Pediatr. Infect. Dis. J. 9:74-79.
6. Al-Orainey, I. O., E. N. S. Saeed, A. M. M. Kambal, and M. E. Eltigani. 1991. Sensitivity of Brucella melitensis to chemotherapeutic agents. Saudi Med. J. 12:119-120.
7. al Sibai, M. B., M. A. Halim, M. M. el Shaker, B. A. Khan, and S. M. Qadri. 1992. Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob. Agents Chemother. 36:150-152.
8. Anonymous. 1986. Joint FAO/WHO expert committee on brucellosis. WHO Tech. Rep. Ser. 740:1-132.
9. Aygen, B., M. Doganay, B. Sumerkan, O. Yildiz, and U. Kayabas. 2002. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med. Mal. Infect. 32:485-493.
10. Bakken, J. S. 2004. The flouroquinolones: how long will their utility last? Scand. J. Infect. Dis. 36:85-92.
11. Bayindir, Y., E. Sonmez, A. Aladag, and N. Buyukberber. 2003. Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: a prospective, randomized study. J. Chemother. 15:466-471.
12. Baykal, M., H. E. Akalin, M. Firat, and A. Serin. 1989. In vitro activity and clinical efficacy of ofloxacin in infections due to Brucella melitensis. Rev. Infect. Dis. 11:S993-S994.
13. Baykam, N., H. Esener, O. Ergonul, S. Eren, A. K. Celikbas, and B. Dokuzoguz. 2004. In vitro antimicrobial susceptibility of Brucella species. Int. J. Antimicrob. Agents 23:405-407.
14. Blain, H., R. Laraki, M. Levy-Soussan, L. T. Du-Boutin, F. Koskas, P. Godeau, and J. C. Piette. 1997. Aneurysm of the thoracic aorta and spondylodiscitis disclosing brucellosis. Rev. Med. Interne 18:876-881.
15. Bodur, H., N. Balaban, S. Aksaray, V. Yetener, E. Akinci, A. Colpan, and A. Erbay. 2003. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand. J. Infect. Dis. 35:337-338.
16. Bodur, H., A. Erbay, E. Akinci, A. Colpan, M. A. Cevik, and N. Balaban. 2003. Neurobrucellosis in an endemic area of brucellosis. Scand. J. Infect. Dis. 35:94-97.
17. Bosch, J., J. Linares, M. J. Lopez de Goicoechea, J. Ariza, M. C. Cisnal, and R. Martin. 1986. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J. Antimicrob. Chemother. 17:459-461.
18. Bosilkovski, M., L. Krteva, S. Caparoska, and M. Dimzova. 2004. Osteoarticular involvement in brucellosis: study of 196 cases in the Republic of Macedonia. Croat. Med. J. 45:727-733.
19. Cakalagaoglu, C., N. Keser, and C. Alhan. 1999. Brucella-mediated prosthetic valve endocarditis with brachial artery mycotic aneurysm. J. Heart Valve Dis. 8:586-590.
20. Colmenero, J. D., M. I. Queipo-Ortuno, R. J. Maria, M. Angel Suarez-Munoz, S. Martin-Carballino, and P. Morata. 2002. Chronic hepatosplenic abscesses in brucellosis. Clinico-therapeutic features and molecular diagnostic approach. Diagn. Microbiol. Infect. Dis. 42:159-167.
21. Dimitrov, T., D. Panigrahi, M. Emara, F. Awni, and R. Passadilla. 2004. Seroepidemiologieal and microbiological study of brucellosis in Kuwait. Med. Princ. Pract. 13:215-219.
22. Doganay, M., and B. Aygen. 1992. Use of ciprofloxacin in the treatment of brucellosis. Eur. J. Clin. Microbiol. Infect. Dis. 11:74-75.
23. Easmon, C. S., J. P. Crane, and A. Blowers. 1986. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J. Antimicrob. Chemother. 18(Suppl. D):43-48.
24. Garcia-Rodriguez, J. A., J. E. Garcia Sanchez, and I. Trujillano. 1991. Lack of effective bactericidal activity of new quinoloncs against Brucella spp. Antimicrob. Agents Chemother. 35:756-759.
25. Garcia-Rodriguez, J. A., J. E. Garcia Sanchez, I. Trujillano, S. E. Garcia, M. I. Garcia Garcia, and M. J. Fresnadillo. 1995. Susceptibilities of Brucella melitensis isolates to clinafloxacin and four other new fluoroquinolones. Antimicrob. Agents Chemother. 39:1194-1195.
26. Garcia-Rodriguez, J. A., J. E. Garcia-Sanchez, I. Trujillano-Martin, E. Garcia-Sanchez, M. I. Garcia-Garcia, and M. J. Fresnadillo. 1994. Activity of BAY y 3118, a novel 4-quinolone, against Brucella melitensis. J. Chemother. 6:102-106.
27. Gobernado, M., E. Canton, and M. Santos. 1984. In vitro activity of ciprofloxacin against Brucella melitensis. Eur. J. Clin. Microbiol. 3:371.
28. Kadikoylu, G., G. Tuncer, Z. Bolaman, and M. Sina. 2002. Brucellar orchitis in Innerwest Anatolia Region of Turkey. A report of 12 cases. Urol. Int. 69:33-35.
29. Kalo, T., S. Novi, A. Nushi, and S. Dedja. 1996. Ciprofloxacin plus doxycycline versus rifampicin plus doxycycline in the treatment of acute brucellosis. Med. Mal. Infect. 26:587-589.
30. Kamoun, S., A. Hammami, S. Ben Hamed, M. M. Sahnoun, F. Elleuch, and M. Daoud. 1991. Brucella endocarditis on Starr aortic valve prosthesis. Arch. Mal. Coeur Vaiss. 84:269-271.
31. Karabay, O., I. Sencan, D. Kayas, and I. Sahin. 2004. Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial. BMC Infect. Dis. 4:18.
32. Khan, M. Y., M. Dizon, and F. W. Kiel. 1989. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis. Antimicrob. Agents Chemother. 33:1409-1410.
33. Khuri-Bulos, N., and K. Shaker. 1991. Relapse of brucellosis following ofloxacin therapy. J. Infect. 22:302-303.
34. Khuri-Bulos, N. A., A. H. Daoud, and S. M. Azab. 1993. Treatment of childhood brucellosis: results of a prospective trial on 113 children. Pediatr. Infect. Dis. J. 12:377-381.
35. Klugman, K. P. 2003. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. Clin. Infect. Dis. 36:783-785.
36. Kocagoz, S., M. Akova, B. Altun, D. Gur, and G. Hascelik. 2002. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin. Microbiol. Infect. 8:240-242.
37. Lang, R., R. Raz, T. Sacks, and M. Shapiro. 1990. Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis. J. Antimicrob. Chemother. 26:841-846.
38. Lang, R., and E. Rubinstein. 1992. Quinolones for the treatment of brucellosis. J. Antimicrob. Chemother. 29:357-360.
39. Lopez-Merino, A., A. Contreras-Rodriguez, R. Migranas-Ortiz, R. Orrantia-Gradin, G. M. Hernandez-Oliva, A. T. Gutierrez-Rubio, and O. Cardenosa. 2004. Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand. J. Infect. Dis. 36:636-638.
40. Manosuthi, W., T. Thummakul, A. Vibhagool, M. Vorachit, and K. Malathum. 2004. Brucellosis: a re-emerging disease in Thailand. Southeast Asian J. Trop. Med. Public Health 35:109-112.
41. Mert, A., F. Kocak, R. Ozaras, F. Tabak, M. Bilir, S. Kucukuglu, R. Ozturk, and Y. Aktuglu. 2002. The role of antibiotic treatment alone for the management of Brucella endocarditis in adults: a case report and literature review. Ann. Thorac. Cardiovasc. Surg. 8:381-385.
42. Micozzi, A., M. Venditti, G. Gentile, N. Alessandri, M. Santero, and P. Martino. 1990. Successful treatment of Brucella melitensis endocarditis with pefloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 9:440-442.
43. Pappas, G., S. Seitaridis, N. Akritidis, and E. Tsianos. 2004. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int. J. Antimicrob. Agents 24:502-507.
44. Qadri, S. M., M. Akhtar, Y. Ueno, and M. B. al Sibai. 1989. Susceptibility of Brucella melitensis to fluoroquinolones. Drugs Exp. Clin. Res. 15:483-485.
45. Qadri, S. M., S. al Sedairy, and Y. Ueno. 1990. Antibacterial activity of lomefloxacin against Brucella melitensis. Diagn. Microbiol. Infect. Dis. 13:277-279.
46. Qadri, S. M., A. Ayub, Y. Ueno, and H. Saldin. 1993. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934). Chemotherapy 39:311-314.
47. Qadri, S. M., M. A. Halim, Y. Ueno, F. M. Abumustafa, and A. G. Postle. 1995. Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy 41:253-256.
48. Qadri, S. M., G. Lee, and L. Brodie. 1989. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates. Drugs Exp. Clin. Res. 15:349-353.
49. Qadri, S. M., G. C. Lee, and M. E. Ellis. 1991. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials. Chemotherapy 37:166-174.
50. Qadri, S. M., and Y. Ueno. 1993. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs. Chemotherapy 39:128-131.
51. Qadri, S. M. H., J. Akhter, Y. Ueno, and H. Saldin. 1993. In vitro activity of 8 fluoroquinolones against clinical isolates of Brucella melitensis. Ann. Saudi Med. 13:37-40.
52. Qadri, S. M. H., B. A. Cunha, M. N. Al Ahdal, Y. Ueno, and S. G. Qadri. 1995. Antibrucella activity of quinolone sparfloxacin. J. Travel Med. 2:229-231.
53. Qadri, S. M. H., and Y. Ueno. 1991. Susceptibility of Brucella melitensis to the new fluoroquinolone CI-960. Drug Investig. 3:365-367.
54. Rubinstein, E., R. Lang, B. Shasha, B. Hagar, L. Diamanstein, G. Joseph, M. Anderson, and K. Harrison. 1991. In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob. Agents Chemother. 35:1925-1927.
55. Saltoglu, N., Y. Tasova, A. S. Inal, T. Seki, and H. S. Aksu. 2002. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med. J. 23:921-924.
56. Solera, J., E. Lozano, E. Martinez-Alfaro, A. Espinosa, M. L. Castillejos, and L. Abad. 1999. Brucellar spondylitis: review of 35 cases and literature survey. Clin. Infect. Dis. 29:1440-1449.
57. Solera, J., E. Martinez-Alfaro, and L. Saez. 1994. Meta-analysis of the efficacy of the combination of rifampicin and doxycycline in the treatment of human brucellosis. Med. Clin. 102:731-738.
58. Solera, J., M. Rodriguez-Zapata, P. Geijo, J. Largo, J. Paulino, L. Saez, E. Martinez-Alfaro, L. Sanchez, M. A. Sepulveda, M. D. Ruiz-Ribo, et al. 1995. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob. Agents Chemother. 39:2061-2067.
59. Sturniolo, G., F. Ricciardi, P. Ruggeri, G. Costantino, G. F. Pellicano, O. Bertuccio, and F. La Rosa. 1993. Treatment of chronic brucellosis with ciprofloxacin. Personal experience. Minerva Med. 84:187-190.
60. Tasova, Y., N. Saltoglu, G. Sahin, and H. S. Aksu. 1999. Osteoarthricular involvement of brucellosis in Turkey. Clin. Rheumatol. 18:214-219.
61. Tekkok, I. H., M. Berker, O. E. Ozcan, T. Ozgen, and E. Akalin. 1993. Brucellosis of the spine. Neurosurgery 33:838-844.
62. Trujillano-Martin, I., E. Garcia-Sanchez, I. M. Martinez, M. J. Fresnadillo, J. E. Garcia-Sanchez, and J. A. Garcia-Rodriguez. 1999. In vitro activities of six new fluoroquinolones against Brucella melitensis. Antimicrob. Agents Chemother. 43:194-195.
63. Tur, B. S., N. Suldur, S. Ataman, E. A. Ozturk, A. Bingol, and M. B. Atay. 2004. Brucellar spondylitis: a rare cause of spinal cord compression. Spinal Cord 42:321-324.
64. Yavuz, T., M. Ozaydin, V. Ulusan, A. Ocal, E. Ibrisim, and A. Kutsal. 2004. A case of mitral stenosis complicated with seronegative Brucella endocarditis. Jpn. Heart J. 45:353-358.
65. Yilmaz, E., M. Parlak, H. Akalin, Y. Heper, C. Ozakin, R. Mistik, B. Oral, S. Helvaci, and O. Tore. 2004. Brucellar spondylitis. Review of 25 cases. J. Clin. Rheumatol. 10:300-307.
66. Yorgancigil, H., G. Yayli, and O. Oyar. 2003. Neglected case of osteoarticular Brucella infection of the knee. Croat. Med. J. 44:761-763.